Aromatherapy

Phase 2Small molecule

SStuart Wright

Aromatherapy is one of 67 small molecule programs targeting Nausea and vomiting. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Coronary Artery BypassActive, not recruiting

Nausea and VomitingPhase 2

Active, not recruiting

Coronary Artery BypassPreclinical

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Aloxi

AAvyxa

Preclinical

27 2

Alfenta

Alnylam Pharmaceuticals

Preclinical

1 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

7 4

Phenergan

BBassett Healthcare

Preclinical

5 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Haldol

DDePuy Orthopaedics

Preclinical

3 7

Adriamycin

GGynecologic Oncology Group

Preclinical

2 8

Cytoxan

BBaxter Healthcare Corporation

Preclinical

2 9

Versed

CConrado Roberto Hoffmann Filho

Preclinical

2 10

Oxycontin

PProtega

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Percutaneous Coronary Intervention1 trial

ARomatherapy for Cognitive Trajectory in Chinese After Percutaneous Coronary Intervention (ARCTIC-PCI)

Unknown status·—·N/A·NCT04103086·660 enrolled

Coronary Artery Bypass1 trial

ARomatherapy for Cognitive Trajectory in Chinese After Coronary Artery Bypass Grafting

Unknown status·—·N/A·NCT04102696·460 enrolled

Nausea and vomiting1 trial

Aromatherapy for Postoperative Nausea and Vomiting in Children

Completed·SStuart Wright·Phase 2·NCT02663154·39 enrolled

Pain1 trial

Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease

Recruiting·UUniversity Hospital, Strasbourg, France·Phase 4·NCT06012097·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Aromatherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aromatherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aromatherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stuart Wright company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SStuart Wright

Aromatherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Percutaneous Coronary Intervention1 trial

Coronary Artery Bypass1 trial

Nausea and vomiting1 trial

Pain1 trial

References

Drug Info

Quick Facts

Related News